Table 1.

Demographics and randomization of study participants

PfSPZ Challenge group	Dose of PfSPZ	Aliquot volume (μL)	PfSPZ/μL/injection	Number of injections	Number of Subjects	Age and range	Gender (no. of female)
A: Medium dose, medium aliquot volume*	10,000	50	100	2	5	35.6 (30–43)	3/5
B: Medium dose, medium aliquot volume	10,000	50	25	8	5	38.2 (28–44)	0/5
C: Medium dose, low aliquot volume	10,000	10	500	2	5	36.6 (21–44)	0/5
D: Medium dose, low aliquot volume	10,000	10	125	8	5	31.6 (22–44)	1/5
E: High dose, low aliquot volume	50,000	10	2,500	2	5	29.2 (24–33)	2/5
F: High dose, low aliquot volume	50,000	10	625	8	5	27.8 (24–32)	5/5

PfSPZ = Plasmodium falciparum sporozoite; RUNMC = Radboud University Nijmegen Medical Center.

^*Group A represents a bridging or reference arm to a previous study performed at RUNMC.⁵